Ceftazidime: Difference between revisions
Gerald Chi (talk | contribs) |
No edit summary |
||
| Line 34: | Line 34: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf | |||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 16:22, 30 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftazidime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negativebacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.
Category
Cephalosporin, Third-Generation
US Brand Names
FORTAZ®, TAZICEF®, CEFTAZIDIME®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanism of action
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf